An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson's disease medication delivered through an infusion pump is safe and effective at reducing ...
DUOPA is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson's disease · In a clinical trial, patients treated with DUOPA ...
An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing ...
An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing ...
Designed for advanced Parkinson’s with poorly controlled motor fluctuations, the infusion delivers steadier levodopa exposure than pills via continuous subcutaneous dosing.
The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are ...
This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major ...
Detecting early rising Parkinson's disease (PD) symptoms could improve treatment outcomes by enabling earlier treatment interventions. In a new eNeuro paper, Daniil Berezhnoi, from Georgetown ...
Among the patients who had post-PEG-J PD diary assessments, one patient did not maintain LCIG monotherapy and started concomitant medication of rotigotine and levodopa on treatment day 60. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results